tbuckley/cabot-search huggingface dataset:
MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
Authors: J. Vansteenkiste, J. Naidoo, C. Faivre-Finn, M. Özgüroğlu, A. Villegas, D. Daniel, S. Murakami, R. Hui, K. Lee, B.C. Cho, K. Kubota, L. Poole, C. Wadsworth, P. Dennis, S. Antonia
Journal: Journal of Thoracic Oncology (2018)
P1.09-32 Classification and Mutation Prediction from Non-Small Cell Lung Cancer Histopathology Images Using Deep Learning
Authors: P. Ocampo, A. Moreira, N. Coudray, T. Sakellaropoulos, N. Narula, M. Snuderl, D. Fenyö, N. Razavian, A. Tsirigos
Journal: Journal of Thoracic Oncology (2018)
P1.13-31 Safety and Tumour Hypoxia Modifying Effect of Buparlisib with Radiotherapy in NSCLC: A Phase I Dose Escalation Study
Authors: M. Skwarski, D. Mcgowan, K. Bradley, J. Fenwick, F. Gleeson, A. Horne, T. Maughan, W. Mckenna, S. Mohammed, R. Muschel, S. Ng, N. Panakis, V. Strauss, R. Stuart, K. Vallis, R. Macpherson, G. Higgins
Journal: Journal of Thoracic Oncology (2018)
P2.06-27 Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epithelioid Malignant Pleural Mesothelioma
Authors: K. Okabe, H. Inokawa, M. Hayashi, R. Okita, M. Furukawa, M. Yamamoto
Journal: Journal of Thoracic Oncology (2018)
Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice
Authors: Tomoko Takano, Eric Bareke, Naoki Takeda, Lamine Aoudjit, Cindy Baldwin, Philip Pisano, Jun Matsuda, Jasmine El Andalousi, Lina Muhtadie, Chantal Bernard, Jacek Majewski, Toru Miyazaki, Ken-ichi Yamamura, Indra R. Gupta
Journal: Kidney International (2018)
P1.13-25 Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study)
Authors: L. Xing, Y. Pan, Y. Shi, Y. Shu, J. Feng, W. Li, L. Cao, L. Wang, W. Gu, Y. Song, J. Yu
Journal: Journal of Thoracic Oncology (2018)
Definitions of response and remission for the Robarts Histopathology Index
Authors: Rish K Pai, Reena Khanna, Geert R D’Haens, William J Sandborn, Jenny Jeyarajah, Brian G Feagan, Niels Vande Casteele, Vipul Jairath
Journal: Gut (2018)

The Robarts Histopathology Index (RHI) is a recently validated instrument that measures histological disease activity in ulcerative colitis.1 Given the increasing importance and use of histology in UC as a treatment outcome, additional evaluation and clarification of the definitions for histological remission and response using the RHI is needed.

During the development of the RHI, we demonstrated that most patients in clinical or endoscopic remission had an RHI≤6. However, an RHI≤6 should not be used to define histological remission as was recently suggested by Magro et al .2 Rather, the minimal criteria for histological remission should be the absence of neutrophils from the mucosa (both lamina propria and epithelium), as neutrophils have long been used to define histologically active disease.3 Furthermore, the presence of mucosal neutrophils in biopsies from patients in clinical remission predicts clinical relapse.4 Using the RHI, an absence of mucosal neutrophils is defined as RHI≤3 with the additional requirement of subscores of 0 for lamina propria neutrophils and 0 for neutrophils in epithelium. Given that basal plasmacytosis has also been suggested as an important histological predictor of adverse outcomes,5 an alternate histological endpoint that requires both the absence of mucosal neutrophils and basal plasmacytosis defined as an RHI≤1 could be attractive. However, this composite definition might be too …
A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region
Authors: K. Fizazi, M. Hussain, F. Saad, N. Shore, U. De Giorgi, E. Efstathiou, U. Ferreira, P. Ivashchenko, K. Madziarska, M. Al-Adhami, K. Modelska, D. Phung, J. Steinberg, C.N. Sternberg
Journal: Annals of Oncology (2018)
P3.01-29 St.Iv Lung Adenocarcinoma Treated by First-Line EGFR–Tyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype
Authors: T. Gil, G. Czyżewicz, M. Skoczek, P. Wójcik, P. Hajder, B. Kołodziejczyk, W. Cieślak, J. Kużdżał
Journal: Journal of Thoracic Oncology (2018)
Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC
Authors: G. Chiritescu, K. Dumon, C. Verslype, G. Houbiers, M. Peeters, J. Janssens, D. van Daele, S. Laurent, J. Arts, K. Hendrickx, I. Borbath, M. Ferrante, F.M. Bastin, J.-C. Goeminne, J.-L. van Laethem, E. Vanderstraeten, J. Decaestecker, W. van Vaerenbergh, B. Delhougne, E. Van Cutsem
Journal: Annals of Oncology (2018)
MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.
Authors: E. Gobbini, P. Pizzutilo, R. Chiari, S. Pilotto, C. Dazzi, G. Osman, P. Bordi, L. Ghilardi, F.L. Cecere, P. Graziano, E. Maiello, G. Borra, O. Martelli, V. Gregorc, V. Scotti, C. Casartelli, F. Riccardi, P. Rizzo, A. Del Conte, A. Delmonte, C. Bareggi, D. Cortinovis, C. Sergi, A. Rossi, G. Rossi, E. Bria, M. Di Maio, S. Novello
Journal: Journal of Thoracic Oncology (2018)
MA25.09 M1b Disease in the 8th Edition of IASLC Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcom
Authors: H. Park, C. Lydon, T. Araki, H. Hatabu, M. Rabin, B. Johnson, M. Nishino
Journal: Journal of Thoracic Oncology (2018)
P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma
Authors: H. Yu, Z. Chen, K. Ballman, M. Watson, R. Govindan, D. Beer, R. Bueno, M. Herman, W. Franklin, D. Gandara, M. Joshi, D. Merrick, W. Richards, C. Rivard, F. Shepherd, M. Tsao, A. Bokhoven, D. Harpole, F. Hirsch
Journal: Journal of Thoracic Oncology (2018)
Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide
Authors: D.V.P. Almeida, C.Z. de Oliveira, R.C. Mariano, F.R. Kater, M.C.L.A. Souza, V.C. Ruiz-Schutz, R. Yamamura, R. Saraiva De Carvalho, F.C. Maluf, A.K. Morgans, S. Srinivas, S. Gupta, T. Dorff, E.Y. Yu, F.A. Schutz
Journal: Annals of Oncology (2018)
Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing
Authors: F. Grossi, C. Genova, D. Cittaro, S. Bonfiglio, S. Boccardo, I. Vanni, M. Mora, M.G. Dal Bello, F. Biello, E. Rijavec, C. Sini, G. Rossi, M. Tagliamento, A. Alama, G. Burrafato, G. Barletta, A. Ballestrero, S. Coco
Journal: Annals of Oncology (2018)
Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
Authors: H. Takahashi, C. Morizane, S. Nomura, N. Okano, M. Tsuda, N. Mizuno, H. Satake, K. Tsuji, K. Shioji, H. Ishii, K. Yasui, H. Miyakawa, A. Ishiguro, T. Ogura, M. Ueno, A. Ikeda, T. Terashima, M. Ikeda, T. Okusaka, J. Furuse
Journal: Annals of Oncology (2018)
Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy
Authors: A. Cercek, G. Dos Santos Fernandes, C. Roxburgh, S. Ng, R. Yaeger, N. Segal, K. Ganesh, D. Reidy, J.J. Smith, G. Nash, J. Guillem, P. Paty, J. Shia, J. Garcia-Aguilar, L. Diaz, C. Crane, K. Goodman, L. Saltz, M. Weiser, Z. Stadler
Journal: Annals of Oncology (2018)
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis
Authors: Jeffrey Hafkin, Norbert Hittel, Alexandra Martin, Rajesh Gupta
Journal: European Respiratory Journal (2018)

<b>Updated data from the Otsuka compassionate use programme show that regimens combining delamanid and bedaquiline appear effective in MDR-TB cases with limited treatment options</b>http://ow.ly/zdE330mlkLN
P1.12-20 Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial
Authors: M. Forster, V. Moreno, E. Calvo, M.E. Olmedo, M.P. Lopez-Criado, J. Lopez-Vilariño, R. Nuñez, C. Kahatt, A. Soto-Matos
Journal: Journal of Thoracic Oncology (2018)
A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
Authors: J.F. Liu, C. Herold, W. Luo, R. Penson, N. Horowitz, P. Konstantinopoulos, C. Castro, J. Curtis, U.A. Matulonis, S. Cannistra, D.S. Dizon
Journal: Annals of Oncology (2018)
Long-term outcomes with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis: 10-year experience in a developing country
Authors: F. Arias, E. Londoño-Schimmer, J. Otero, C.E. Cétares, G.E. Herrera, M. Mora, P. Rodriguez, M. Mejía, J.D. Guerra, A. Ruiz-Patiño, A.F. Cardona Zorrilla
Journal: Annals of Oncology (2018)
P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
Authors: J. Neal, R. Doebele, G. Riely, A. Spira, L. Horn, Z. Piotrowska, D. Costa, S. Zhang, D. Bottino, J. Zhu, D. Kerstein, S. Li, P. Jänne
Journal: Journal of Thoracic Oncology (2018)
Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study
Authors: M. Takahashi, K. Inoue, H. Mukai, T. Yamanaka, C. Egawa, Y. Sakata, H. Ikezawa, T. Matsuoka, J. Tsurutani
Journal: Annals of Oncology (2018)
Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors
Authors: A. Puccini, K. Poorman, R. Goldberg, A.F. Shields, M. Winerip, W.M. Korn, M.D. Berger, R. Tokunaga, M. Naseem, F. Battaglin, W. Zhang, S. Soni, J.J. Hwang, P. Philip, J.L. Marshall, H.-J. Lenz
Journal: Annals of Oncology (2018)
p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan
Authors: R. Takahashi, T. Wakatsuki, N. Yamamoto, S. Taguchi, E. Shinozaki, H. Osumi, M. Ogura, T. Ichimura, D. Takahari, M. Suenaga, K. Chin, M. Oguchi, M. Ueno, K. Yamaguchi
Journal: Annals of Oncology (2018)
Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study
Authors: J.A. Ledermann, R. Shapira-Frommer, A. Santin, A.S. Lisyanskaya, S. Pignata, I. Vergote, F. Raspagliesi, G.S. Sonke, M.J. Birrer, D.M. Provencher, J. Sehouli, N. Colombo, A. González-Martín, A. Oaknin, P.B. Ottevanger, V. Rudaitis, R. Cristescu, J. Kobie, J. Ruman, U.A. Matulonis
Journal: Annals of Oncology (2018)
MA01.03 An Externally Validated Nomogram for Predicting Distant Metastasis After SBRT for Early Stage Non-Small Cell Lung Cancer
Authors: A. Juloori, A. Zajichek, M. Kattan, D. Mullen, P. Samson, N. Woody, M. Roach, J. Bradley, G. Videtic, C. Robinson, K. Stephans
Journal: Journal of Thoracic Oncology (2018)
P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients
Authors: F. Barlesi, L. Paz-Ares, D. Page, A. Shewade, P. Lambert, T. Mughal, L. Gay, M. Khorshid, B. Arnieri, W. Capra, S. Foser, C. Mascaux, L. Bubendorf, L. Wang
Journal: Journal of Thoracic Oncology (2018)
EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC)
Authors: M.R. Harrison, P.G. Davis, M.G. Khouri, R.T. Gupta, A.J. Armstrong, M.A. McNamara, T. Zhang, M. Anand, K. Onyenwoke, H. Hood, S. Edwardson, D. Craig, Y. Wu, P. Healy, B. Coyne, L. Jones, D.J. George
Journal: Annals of Oncology (2018)
Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)
Authors: J. Pfisterer, A.P. Dean, K. Baumann, J. Rau, P. Harter, F. Joly, J. Sehouli, U. Canzler, B. Schmalfeldt, C. Shannon, A. Hein, D.U. Reimer, L.C. Hanker, T. Petit, F. Marmé, A. El-Balat, R. Glasspool, N. de Gregorio, S. Mahner, J.-E. Kurtz
Journal: Annals of Oncology (2018)
Targeted therapy based on the genetic alterations prolongs the progression-free survival of patients with advanced biliary tract cancer
Authors: F. Feng, Q. Cheng, D. Zhang, B. Li, H. Qin, C. Xu, M. Han, Y. Yu, Z. Li, J.-Y. Li, Z. Qiu, L. Xiong, C. Liu, F. Li, B. Yi, X. Jiang
Journal: Annals of Oncology (2018)
Multiplex immunoassays analysis of plasma biomarker levels and response to neoadjuvant chemotherapy for locally advanced breast cancer
Authors: J.H. Cho, K. Park, E. Lee, Y. Kim, S. Park, S.E. Yoon, K.K. Lee, J.Y. Hur, S.K. Lee, J.E. Lee, S.W. Kim, S.J. Nam, J. Yu, J.-Y. Kim, H.H. Jung, Y.H. Park
Journal: Annals of Oncology (2018)
Benefits of supervised community physical activity in obstructive sleep apnoea
Authors: Mathieu Berger, Jean-Claude Barthélémy, David Hupin, Jérémy Raffin, Caroline Dupré, Pierre Labeix, Frédéric Costes, Jean-Michel Gaspoz, Frédéric Roche
Journal: European Respiratory Journal (2018)

Obstructive sleep apnoea (OSA) is a chronic disorder characterised by repetitive episodes of partial or complete airway obstruction occurring during sleep [1]. Recent data suggest that moderate-to-severe OSA is highly prevalent, affecting up to 50% of males and 25% of females [2]. OSA is associated with frequent cardiovascular and cerebrovascular events [3]. Although continuous positive airway pressure (CPAP) is the gold standard treatment, long-term adherence remains poor, particularly in moderate and in non-sleepy patients [4], while the cardiovascular risk remains high. Long-term physical activity programmes outside of hospitals may help improve moderate obstructive sleep apnoea, particularly in obese patients <http://ow.ly/11jg30lOJYS> We thank all the participants for their commitment and their willingness, Arnaud Garcin for study coordination, Laurent Tordella for data management, Mathilde Donnat and Hayet Iddir for their involvement in the data collection, and Audrey Laligant and Isabelle Goure (all at CHU Saint-Etienne, Saint-Etienne, France) for the diet educational group sessions. We are grateful for the involvement of the Fédération Française d'Education Physique et de Gymnastique Volontaire (FFEPGV) Loire clubs' leaders and sports instructors, which made the study possible. We thank Resmed, and the Home Care Service Company Vivisol and VitalAire for the loan of portable sleep monitoring.
Outcomes of ovarian clear cell carcinoma (OCCC) of the Vall d’Hebron Hospital/Vall d’Hebron Institute of Oncology (VHIO)
Authors: F. Amair Pinedo, L. Fariñas-Madrid, V. Rodriguez Freixinos, F.J. Ros Montañá, G. Villacampa, R. Dienstmann, A. Oaknin
Journal: Annals of Oncology (2018)
P1.01-54 A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
Authors: D. Graham, E. Chen, K. Pisters, P. Bradbury, M. Trinkaus, M. Chan, S. Arif, U. Zurawska, J. Rothenstein, D. Zawisza, S. Effendie, M. Sawczak, N. Leighl
Journal: Journal of Thoracic Oncology (2018)
OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC
Authors: G. Durm, S. Althouse, A. Sadiq, S. Jalal, S. Jabbour, R. Zon, G. Kloecker, W. Fisher, K. Reckamp, E. Kio, R. Langdon, B. Adesunloye, R. Gentzler, N. Hanna
Journal: Journal of Thoracic Oncology (2018)
Abstract 14026: The Impact of Hemoglobin Drop, Bleeding Events and Blood Transfusion on Long Term Mortality Following Transcatheter Aortic Valve Implantation
Authors: Maayan Konigstein, Ofer Havakuk, Ariel Finkelstein, Jeremy Ben shoshan, Gad Keren, Shmuel Banai
Journal: Circulation (2015)

Background: Despite the minimally invasive nature of trans-catheter aortic valve implantation (TAVI), the procedure is associated with several complications. We analyzed the individual impact of bleeding events, hemoglobin (Hb) drop, and Red Blood Cells (RBC) transfusions on prognosis. Methods and results: Consecutive patients (n=597) undergoing trans-femoral TAVI were prospectively enrolled. Peri-procedural Hb levels, RBC transfusions and major/life threatening bleeding events were documented and analyzed. To study the relationship between Hb drop, RBC transfusions and long-term mortality, the entire cohort was divided into 4 groups according to Hb drop (less or ≥ than 3 g/dl), and receiving RBC transfusion (yes /no). In the entire cohort mean Hb level decreased following TAVI (11.8±1.4 to 9.5 ±1.3 g/dl; p&lt;0.001). Major/ life threatening bleedings occurred in 66 (10.1%) patients, and 179 (30%) patients received RBC transfusions. Major/life threatening bleedings were not independently associated with mortality when adjusted to Hg drop and RBC transfusion. Among patients with Hb drop of &lt; 3 g/dl, those who received blood transfusion had higher mortality (HR 1.9 CI 1.2-2.9; p=0.004). Among patients with Hb drop of ≥ 3 g/dl, the Hb drop had no significant impact on survival (HR 1.5 CI 0.7-2.9; p=0.2), however, patients that received blood transfusions had a significantly higher mortality (HR 4.1 CI 2.2-7.7; p&lt;0.001). Conclusion: Hb drop is frequently observed following TAVI. RBC transfusion is strongly associated with increased long-term mortality in these patients, regardless of the degree of Hb drop.
P2.04-14 Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit from Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Authors: S. Rothschild, P. Jermann, S. Savic, K. Mertz, A. Zippelius, L. Quagliata, L. Bubendorf
Journal: Journal of Thoracic Oncology (2018)
Molecular profiles as a function of treatment response/progression free survival in a prospective cervical cancer study (RAIDs)
Authors: S. Scholl, L. De Koning, M. Popovic, D.L.R. Anne, A. Floquet, E. Berns, G. Kenter, A. Kereszt, E. Girard, H. von der Leyen, S. Dureau, V. Fourchotte, R. Rouzier, M. Kamal, R. Consortium
Journal: Annals of Oncology (2018)
Can we predict tuberculosis cure? What tools are available?
Authors: Delia Goletti, Cecilia S. Lindestam Arlehamn, Thomas J. Scriba, Richard Anthony, Daniela Maria Cirillo, Tonino Alonzi, Claudia M. Denkinger, Frank Cobelens
Journal: European Respiratory Journal (2018)

Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2–3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies. In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of “cure”. Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.
P1.16-12 Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit from Adjuvant Chemotherapy
Authors: S. Grieve, M. Finniss, A. Ray, J. Moore, A. Muragesan, J. Agar, C. Acar, T. Reiman
Journal: Journal of Thoracic Oncology (2018)
MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases
Authors: M. Geier, R. Descourt, R. Corre, G. Léveiller, R. Lamy, E. Goarant, J. Bizec, C. Bernier, G. Quéré, F. Couturaud, G. Robinet
Journal: Journal of Thoracic Oncology (2018)
Plant-Derived Exosomal MicroRNAs Shape the Gut Microbiota
Authors: Yun Teng, Yi Ren, Mohammed Sayed, Xin Hu, Chao Lei, Anil Kumar, Elizabeth Hutchins, Jingyao Mu, Zhongbin Deng, Chao Luo, Kumaran Sundaram, Mukesh K. Sriwastva, Lifeng Zhang, Michael Hsieh, Rebecca Reiman, Bodduluri Haribabu, Jun Yan, Venkatakrishna Rao Jala, Donald M. Miller, Kendall Van Keuren-Jensen, Michael L. Merchant, Craig J. McClain, Juw Won Park, Nejat K. Egilmez, Huang-Ge Zhang
Journal: Cell Host & Microbe (2018)

Highlights•Plant exosome-like nanoparticles (ELNs) are taken up by gut bacteria•The lipid composition of ELNs determines uptake by specific bacteria•ELN RNAs affect bacterial genes, notably affecting Lactobacillus production of I3A•ELN-mediated I3A alterations affect IL-22 production, resulting in ameliorated colitisSummaryThe gut microbiota can be altered by dietary interventions to prevent and treat various diseases. However, the mechanisms by which food products modulate commensals remain largely unknown. We demonstrate that plant-derived exosome-like nanoparticles (ELNs) are taken up by the gut microbiota and contain RNAs that alter microbiome composition and host physiology. Ginger ELNs (GELNs) are preferentially taken up by Lactobacillaceae in a GELN lipid-dependent manner and contain microRNAs that target various genes in Lactobacillus rhamnosus (LGG). Among these, GELN mdo-miR7267-3p-mediated targeting of the LGG monooxygenase ycnE yields increased indole-3-carboxaldehyde (I3A). GELN-RNAs or I3A, a ligand for aryl hydrocarbon receptor, are sufficient to induce production of IL-22, which is linked to barrier function improvement. These functions of GELN-RNAs can ameliorate mouse colitis via IL-22-dependent mechanisms. These findings reveal how plant products and their effects on the microbiome may be used to target specific host processes to alleviate disease.Graphical abstract
Comprehensive geriatric assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): A mono-institutional experience
Authors: G. Lombardi, E. Bergo, L. Bellu, M. Caccese, A. Lettiero, G. Tierno, A. Pambuku, A. Brunello, V. Zagonel
Journal: Annals of Oncology (2018)
Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Authors: G.D. Demetri, L. Paz-Ares, A.F. Farago, S.V. Liu, S.P. Chawla, D. Tosi, E.S. Kim, C. Blakely, J.C. Krauss, D. Sigal, L. Bazhenova, T. John, B. Besse, J. Wolf, T. Seto, E. Chow-Maneval, P.S. Multani, A.D. Johnson, B. Simmons, R.C. Doebele
Journal: Annals of Oncology (2018)
P1.03-31 Periostin is a Negative Prognostic Factor and Promotes Cancer Cell Proliferation in Non-Small Cell Lung Cancer
Authors: T. Okazaki, K. Tamai, R. Shibuya, M. Nakamura, M. Mochizuki, K. Yamaguchi, J. Abe, S. Takahashi, K. Satoh
Journal: Journal of Thoracic Oncology (2018)
MA24.09 Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small Cell Lung Cancer with an Altered Metabolism
Authors: S. Best, D. Desouza, A. Kersbergen, A. Policheni, S. Dayalan, D. Tull, V. Rathi, D. Gray, M. Ritchie, M. Mcconville, K. Sutherland
Journal: Journal of Thoracic Oncology (2018)
P1.16-64 The Histological Predominant Pattern Could Predict Site of Recurrence and Metastasis in Surgically Treated Stage I Adenocarcinoma of the Lung
Authors: F. Guerrera, V. Marchese, F. Lococo, O. Rena, L. Ampollini, J. Vannucci, L. Errico, P. Bertoglio, P. Lausi, L. Ventura, A. Viti, M. Paci, P.L. Filosso, A. Oliaro, C. Casadio, F. Puma, F. Ardissone, E. Ruffini
Journal: Journal of Thoracic Oncology (2018)